2022 – Page 4 – State Expert Center of the Ministry of Health of Ukraine

Changes to safety information for medicinal products containing enoxaparin (enoxaparin) following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 25 – October 28, 2021

14.09.2022 1619

The European Medicines Agency (EMA) has published the minutes of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting of 25 – 28 October 2021…

Changes to safety information for medicinal products containing bimatoprost (bimatoprost) following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 25 – October 28, 2021

14.09.2022 1385

The European Medicines Agency (EMA) has published the minutes of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting of 25 – 28 October 2021…

Update of safety information for medicinal products containing ocrelizumab (ocrelizumab) following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 25 – October 28, 2021

14.09.2022 1105

The European Medicines Agency (EMA) has published the minutes of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting of 25 – 28 October 2021…

Changes to the safety information of medicinal products containing dimethyl fumarate following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 25 – 28 October 2021

14.09.2022 1265

The European Medicines Agency (EMA) has published the minutes of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting of 25 – 28 October 2021…

On amending the instructions for medical use of medicinal products containing upadacitinib (upadacitinib)

14.09.2022 1371

Taking into account the report of the Pharmacovigilance Risk Assessment Committee (PRAC) based on the assessment of the analysis of Periodic Safety Update Reports…

Report on the meeting of the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) held on 19-20 July 2022

09.09.2022 7218

Nonsteroidal anti-inflammatory drugs (NSAIDs) for systemic use and their use during pregnancy. In July 2022, PRAC gave recommendations…

On amending the instructions for medical use of medicinal products containing teicoplanin (teicoplanin)

09.09.2022 1712

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products that…

Regarding amendments to the instructions for medical use of medicinal products containing rabeprazole (rabeprazole)

09.09.2022 1613

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing…

Regarding amendments to the package leaflets of medicinal products containing methylphenidate (methylphenidate)

09.09.2022 3324

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the assessment of the analysis of Periodic Safety Update Reports (PSURs) for medicinal products,…

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting of 4-7 July 2022

24.08.2022 1292

Medicinal products containing nomegestrol or chlormadinone: PRAC recommends new measures to minimize the risk of meningioma PRAC recommended…

Changes to safety information for medicinal products containing enoxaparin (enoxaparin) following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 25 – October 28, 2021

Changes to safety information for medicinal products containing bimatoprost (bimatoprost) following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 25 – October 28, 2021

Update of safety information for medicinal products containing ocrelizumab (ocrelizumab) following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 25 – October 28, 2021

Changes to the safety information of medicinal products containing dimethyl fumarate following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 25 – 28 October 2021

On amending the instructions for medical use of medicinal products containing upadacitinib (upadacitinib)

Report on the meeting of the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) held on 19-20 July 2022

On amending the instructions for medical use of medicinal products containing teicoplanin (teicoplanin)

Regarding amendments to the instructions for medical use of medicinal products containing rabeprazole (rabeprazole)

Regarding amendments to the package leaflets of medicinal products containing methylphenidate (methylphenidate)

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting of 4-7 July 2022

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration